@hikazori Just wish to know your thoughts on the MRSA market . . . the P2 MRSA results were statistically significantly 43% higher than antibiotic alone which should offer more than ' . . . just a glimmer of hope' for CFRX. Isn't this company worth investing in with preliminary results due out March 2020? Thank you Stephen
  • 6